Header Logo

Connection

JOHN KIRKWOOD to Immunoconjugates

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Immunoconjugates.
JOHN KIRKWOOD
Connection Strength
0.151
Immunoconjugates
  1. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 07; 19(7):916-929.
    View in: PubMed
    Score: 0.151
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.